Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Apr 28, 2016
Heptares CSO and Co-founder - Dr Fiona Marshall - Elected as a Fellow of The Academy of Medical Sciences
Apr 25, 2016
Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

Jun 12-15, 2016
Developments in Protein Interaction Analysis
Berlin, Germany
Presenting: Andrei Zhukov

Jun 13-15, 2016
IBC’s 11th Annual Next Generation Protein Therapeutics Summit
San Francisco, CA, USA
Presenting: Cath Hutchings

© 2012-2016 Heptares Therapeutics